MAP3K5 and amyotrophic lateral sclerosis: Within Table 1, DNM3TA, ERN1, HSPD1, PPIA, VCP, MAP3K5, MAKPK1, NOS1, PTK2, PTPRC, and RARA were previously identified high-confidence therapeutic targets from iPSC-differentiated motor neurons (diMN)-derived and CNS data that belonged to the druggable classes defined by PandaOmics, with supportive evidence on their ALS or neurodegeneration, and ranked as the top-50 targets in at least one of the meta-analyses (Pun et al., 2022).